Market Newsdesk

MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that two leading physicians in the field of sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire in Vice President, Senior Medical Director roles, effective April 21 and June 2 respectively.  

“Dr. Hoff and Dr. Patel are widely regarded as experts and thought leaders in their respective fields, and we are excited to bring their expertise and passion to the Inspire team. Dr. Hoff and Dr. Patel are both highly experienced in treating sleep apnea patients including extensive work with Inspire therapy. They will play key roles in guiding Inspire’s medical education, training and future technology developments to drive continued adoption of Inspire therapy,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire.

Dr. Hoff received his Doctor of Medicine (M.D.) degree from the University of Michigan Medical School with honors and completed his residency at Michigan. Upon completion of his training, he joined Michigan Otolaryngology Surgery Associates as a comprehensive otolaryngologist with a special interest in sleep apnea. He joined the faculty at the University of Michigan in 2014, where he is currently an Associate Professor.

Dr. Hoff has been involved in leadership positions during his career both regionally as President of the Michigan Otolaryngology Society and internationally as President of the International Surgical Sleep Society (ISSS) and has been in clinical practice for over 25 years.

“I am very honored to join Inspire. My career has focused on driving innovation and improved outcomes for patients with obstructive sleep apnea, a vision shared by the leadership and team members at Inspire. I look forward to bringing my experience in the field of sleep surgery to help guide Inspire in their mission of serving the many patients with untreated OSA,” said Dr. Hoff.   

Dr. Patel earned his Doctor of Medicine (M.D.) degree from the Royal College of Surgeons in Ireland, followed by a residency in Internal Medicine at Henry Ford Hospital in Detroit. Dr. Patel then completed a fellowship in Sleep Disorders Medicine at Rush University Medical Center in Chicago.

Dr. Patel founded The Insomnia and Sleep Institute of Arizona, a leading practice dedicated to evidence-based approaches to treat sleep disorders. He has served as a principal investigator in multiple clinical trials in sleep medicine and neuromodulation and is a published researcher in the field of hypoglossal nerve stimulation. Dr. Patel is a highly sought after lecturer on the topics of precision sleep medicine and neuromodulation and has been in clinical practice for over 15 years.

“Inspire has redefined what’s possible in sleep medicine, and I’m truly honored and excited to be able to contribute to a future where technology and compassionate care come together to transform lives on a global scale,” said Dr. Patel.

Both Dr. Hoff and Dr. Patel will maintain their clinical practices independent from Inspire.

About Inspire Medical Systems

Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the factors identified under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC, and as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website at www.inspiresleep.com. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

Investor and Media Contact

Ezgi Yagci
Vice President, Investor Relations
[email protected]
617-549-2443

PALM BEACH GARDENS, Fla., April 21, 2025 (GLOBE NEWSWIRE) — ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced the launch of its Immediate Molar Implant System in the United States. ZimVie is expanding its already clinically proven TSX^® and T3 PRO^® Implant systems with an immediate molar solution, simplifying challenging clinical scenarios for providers and shortening treatment times for patients requiring molar implants.

Immediately replacing extracted molars with an implant can be difficult due to the complex multi-rooted anatomy and size of the tooth socket. ZimVie’s Immediate Molar Implant System includes specially engineered instrumentation that streamlines site preparation in molar extraction, making it a more controlled and predictable procedure. The system also offers optimized wide-diameter implants that better fit the implant site for unmatched primary stability while potentially reducing the risk of peri-implantitis by up to 20% through its proprietary DAE coronal surface technology. Restorative compatibility with ZimVie’s existing implant system minimizes switching costs.

Conventional treatment protocols involve molar extraction, followed by months of healing before an implant can be placed. The ZimVie Immediate Molar Implant System allows the implant to be restored in half the time compared to traditional treatment, in a simplified, predictable manner.

“The launch of our Immediate Molar Dental Implant System marks a significant milestone in our commitment to advancing dental technology,” said ZimVie CEO Vafa Jamali. “We have expanded the offering of our implant systems to address the unique challenges of molar tooth restoration and provide patients shorter and more cost-effective treatment while delivering a more predictable, lasting outcome.”

For more information on ZimVie’s dental implants, suite of connected solutions, and continuing education, please visit www.zimvie.com.

Immediate Molar Implant System

A Media Snippet accompanying this announcement is available by clicking on this link.

About TSX Implants

Launched in 2022, TSX Implants are designed for immediate extraction and standard loading protocols as well as placement predictability and primary stability in soft and dense bone. The Implant incorporates features with more than two decades of real-world, clinical data to deliver peri-implant health, crestal bone maintenance, long-term osseointegration, and prosthetic stability,* including the Contemporary Hybrid Surface combination with coronal DAE. Integrated with ZimVie’s end-to-end digital workflows and engineered with surgical and restorative versatility, the TSX Implant furthers ZimVie’s commitment to simplify procedures and optimize practice protocols.

About T3 PRO Implants

Launched in 2022, the T3 PRO Implant’s advanced design delivers high primary stability and allows for immediate function. T3 PRO has a hybrid surface featuring the proprietary Osseotite surface on the implant collar, as well as a rougher grit-blasted implant body. Not only have multiple long-term, independent clinical studies on the proprietary Osseotite surface demonstrated safety and performance,* they have also demonstrated the effect of this surface in preserving crestal bone. This Contemporary Hybrid Surface of T3 PRO along with the optional integrated platform switching design has also been shown to provide early and long-term peri-implant bone support.

* References on file at ZimVie.

About ZimVie

ZimVie is a global life sciences leader in the dental implant market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.zimvie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning ZimVie’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs, expectations, and assumptions of management and are subject to significant risks, uncertainties, and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. For a list and description of some of such risks and uncertainties, see ZimVie’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in ZimVie’s filings with the SEC. Forward-looking statements speak only as of the date they are made, and ZimVie disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release.

Media Contact Information:

ZimVie

Grace Flowers • [email protected]
(561) 319-6130

Investor Contact Information:

Gilmartin Group LLC

Webb Campbell • [email protected]

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/99f92dfd-d794-4c29-96e4-209f3a10cd03

First Quarter 2025 Performance and Operational Highlights

• Net income of
  $10.4
  million, or
  $1.03
  per diluted share
• Core net income
  
  ⁽¹⁾
  
  of
  $10.3
  million, or
  $1.03
  per diluted share
  
  ⁽¹⁾
  
• Pretax pre-provision core net income
  
  ⁽¹⁾
  
  of
  $14.2
  million
• Net interest income of $
  24.9
  million,
  a decrease
  of $
  171,000
  from the prior quarter
• Net interest margin (“NIM”) of
  3.75%
  ,
  up
  9
  basis points from the prior quarter
• Return on average assets (“ROAA”) of
  1.48%
  ; return on average stockholders’ equity (“ROAE”) of
  14.67%
  ; and return on average tangible common equity (“ROATCE”)
  
  ⁽¹⁾
  
  of
  17.19%
• Core ROAA
  
  ⁽¹⁾
  
  of
  1.47%
  ; and core ROATCE
  
  ⁽¹⁾
  
  of
  17.16%
• Efficiency ratio of
  46.42%
• Linked-quarter loa
  ns grew
  6.1%
  annualized
• Linked-quarter deposits grew
  2.4%
  annualized

^{(1) See “Reconciliation of Non-GAAP Financial Measures” below for reconciliation of non-GAAP financial measures to their most closely comparable GAAP financial measures.} 

ANNISTON, Ala., April 21, 2025 (GLOBE NEWSWIRE) — Southern States Bancshares, Inc. (NASDAQ: SSBK) (“Southern States” or the “Company”), the holding company for Southern States Bank, an Alabama state-chartered commercial bank (the “Bank”), today reported net income of $10.4 million, or $1.03 diluted earnings per share, for the first quarter of 2025. This compares to net income of $11.2 million, or $1.11 diluted earnings per share, for the fourth quarter of 2024, and net income of $8.1 million, or $0.90 diluted earnings per share, for the first quarter of 2024. The Company reported core net income of $10.3 million, or $1.03 diluted core earnings per share, for the first quarter of 2025. This compares to core net income of $10.5 million, or $1.04 diluted core earnings per share, for the fourth quarter of 2024, and core net income of $8.1 million, or $0.90 diluted core earnings per share, for the first quarter of 2024 (see “Reconciliation of Non-GAAP Financial Measures”).

As previously disclosed on March 31, 2024, FB Financial Corporation, the parent company of FirstBank, and Southern States, jointly announced their entry into a definitive merger agreement pursuant to which Southern States will be merged with and into FB Financial (the “Merger”).

CEO Commentary
Mark Chambers, President and Chief Executive Officer said, “In the first quarter, we reported net income of $10.4 million and diluted EPS of $1.03, which was supported by a 9 basis point improvement in net interest margin and lower noninterest expense. We’re particularly encouraged by the continued improvement in our deposit costs and the exceptionally low level of non-performing loans, which reflects our prudent credit culture and strong risk management.”
“We are embarking on an exciting new chapter for our bank, our customers, our employees and the communities we proudly serve. Joining forces with Nashville-based FB Financial, which has $13 billion in total assets and operates as FirstBank, is an ideal combination.  We are culturally aligned in our customer-centric philosophy. We are geographically committed to serving vibrant communities in the South, which now includes Tennessee, Kentucky, Alabama, and Georgia. This merger allows us to expand our capabilities, enhance the customer experience, and continue delivering the trusted, relationship-based banking our clients have come to expect. While our name may change, our commitment to our customers and communities remains stronger than ever.”

Net Interest Income and Net Interest Margin

	Three Months Ended												% Change March 31, 2025 vs.
	March 31, 2025				December 31, 2024				March 31, 2024				December 31, 2024		March 31, 2024
	(Dollars in thousands)
Average interest-earning assets	$	2,690,714			$	2,722,907			$	2,336,369			(1.2) %		15.2	%
Net interest income	$	24,879			$	25,050			$	20,839			(0.7) %		19.4	%
Net interest margin		3.75	%			3.66	%			3.59	%		9 bps		16 bps

Net interest income for the first quarter of 2025 was $24.9 million, a decrease of 0.7% from $25.1 million for the fourth quarter of 2024. The decrease was primarily driven by a lower yield on interest-earning assets resulting from lower interest rates on loans and a reduction in other interest-earning assets earning lower interest rates, which was significantly offset by a lower cost of interest-bearing deposits primarily resulting from lower interest rates.

Relative to the first quarter of 2024, net interest income increased $4.0 million, or 19.4%. The increase was mainly driven by significant organic growth, coupled with the acquisition of Century Bank on July 31, 2024.

Net interest margin for the first quarter of 2025 was 3.75%, compared to 3.66% for the fourth quarter of 2024. The increase was primarily due to a reduction in earning assets, coupled with cost savings attributed to calls and repayments at maturity on higher-cost brokered deposits.

Relative to the first quarter of 2024, net interest margin increased from 3.59% to 3.75%. The increase in the margin was primarily the result of a decrease in interest rates paid on interest-bearing deposits. The acquisition of Century Bank resulted in a positive impact to the net interest margin, helping to reduce the cost of interest-bearing liabilities.

Noninterest Income

	Three Months Ended											% Change  March 31, 2025  vs.
	March 31, 2025				December 31, 2024			March 31, 2024				December 31, 2024			March 31, 2024
	(Dollars in thousands)
Service charges on deposit accounts	$	564			$	565		$	463			(0.2) %			21.8	%
Swap (expenses) fees		(3	)			17			15			(117.6) %			(120.0) %
SBA/USDA fees		40				89			64			(55.1) %			(37.5) %
Mortgage origination fees		80				55			96			45.5  %			(16.7) %
Net gain (loss) on securities		23				25			(12	)		(8.0) %			291.7	%
Employee retention credit (“ERC”)		—				1,154			—			N/A			N/A
Other operating income		949				1,085			642			(12.5) %			47.8	%
Total noninterest income	$	1,653			$	2,990		$	1,268			(44.7) %			30.4	%

Noninterest income for the first quarter of 2025 was $1.7 million, a decrease of 44.7% from $3.0 million for the fourth quarter of 2024. The Company applied for the Voluntary Disclosure Program (“VDP”) associated with the ERC program during the third quarter of 2023 and received approval during the fourth quarter of 2024. The fourth quarter of 2024 included $1.2 million in ERC as a participant in the program.

Relative to the first quarter of 2024, noninterest income increased 30.4% from $1.3 million. The acquisition of Century Bank on July 31, 2024 contributed to additional noninterest income during the first quarter of 2025.

Noninterest Expense

	Three Months Ended									% Change  March 31, 2025  vs.
	March 31, 2025			December 31, 2024			March 31, 2024			December 31, 2024		March 31, 2024
	(Dollars in thousands)
Salaries and employee benefits	$	6,924		$	7,002		$	6,231		(1.1) %		11.1	%
Equipment and occupancy expenses		828			851			689		(2.7) %		20.2	%
Data processing fees		909			960			643		(5.3) %		41.4	%
Regulatory assessments		429			441			360		(2.7) %		19.2	%
Professional fees related to ERC		—			236			—		N/A		N/A
Other operating expenses		3,216			3,584			2,452		(10.3) %		31.2	%
Total noninterest expenses	$	12,306		$	13,074		$	10,375		(5.9)        %		18.6	%

Noninterest expense for the first quarter of 2025 was $12.3 million, a decrease of 5.9% from $13.1 million for the fourth quarter of 2024. The fourth quarter of 2024 included professional fees paid to a third party related to ERC, as well as additional expenses related to a nonperforming loan that is in collection, legal fees and fraud/forgery losses, compared to the first quarter of 2025.

Relative to the first quarter of 2024, noninterest expense increased 18.6% from $10.4 million. The acquisition of Century Bank on July 31, 2024 contributed to additional noninterest expense during the first quarter of 2025.

Loans and Credit Quality

	Three Months Ended												% Change  March 31, 2025  vs.
	March 31, 2025				December 31, 2024				March 31, 2024				December 31, 2024			March 31, 2024
	(Dollars in thousands)
Gross loans	$	2,266,740			$	2,233,244			$	1,971,396			1.5	%		15.0	%
Unearned income		(6,704	)			(6,675	)			(6,247	)		0.4	%		7.3	%
Loans, net of unearned income (“Loans”)		2,260,036				2,226,569				1,965,149			1.5	%		15.0	%
Average loans, net of unearned (“Average loans”)	$	2,235,194			$	2,205,892			$	1,916,288			1.3	%		16.6	%
Nonperforming loans (“NPL”)	$	7,175			$	6,533			$	3,446			9.8	%		108.2	%
Provision for credit losses	$	775			$	72			$	1,236			976.4	%		(37.3) %
Allowance for credit losses (“ACL”)	$	28,876			$	28,338			$	25,144			1.9	%		14.8	%
Net charge-offs (recoveries)	$	237			$	(205	)		$	470			215.6	%		(49.6) %
NPL to gross loans		0.32	%			0.29	%			0.17	%
Net charge-offs (recoveries) to average loans(1)		0.04	%		(0.04) %					0.10	%
ACL to loans		1.28	%			1.27	%			1.28	%
(1) Ratio is annualized.

Loans, net of unearned income, were $2.3 billion at March 31, 2025, up $33.5 million from December 31, 2024 and up $294.9 million from March 31, 2024. The linked-quarter increase in loans was attributable to new business growth across our footprint. The year-over-year increase in loans was primarily attributable the new business growth across our footprint, coupled with the acquisition of Century Bank, which resulted in additional loans of $134.0 million at March 31, 2025.

Nonperforming loans totaled $7.2 million, or 0.32% of gross loans, at March 31, 2025, compared with $6.5 million, or 0.29% of gross loans, at December 31, 2024, and $3.4 million, or 0.17% of gross loans, at March 31, 2024. The $642,000 net increase in nonperforming loans in the first quarter was primarily attributable to one significant commercial real estate loan being placed on nonaccrual status. The $3.7 million net increase in nonperforming loans from March 31, 2024 was primarily attributable to one significant commercial and industrial loan and the aforementioned commercial real estate loan being placed on nonaccrual status. These increases were partially offset by a commercial and industrial loan that was charged-off.

The Company recorded a provision for credit losses of $775,000 for the first quarter of 2025, compared to $72,000 for the fourth quarter of 2024. Provision in the first quarter of 2025 was based on loan growth, qualitative economic factors and individually analyzed loans.

Net charge-offs for the first quarter of 2025 were $237,000, or 0.04% of average loans on an annualized basis, compared to net recoveries of $205,000, or (0.04)% of average loans on an annualized basis, for the fourth quarter of 2024, and net charge-offs of $470,000, or 0.10% of average loans on an annualized basis, for the first quarter of 2024. The net charge-offs recorded during the first quarter of 2025 were substantially related to a commercial and industrial loan. The net recoveries received in the fourth quarter of 2024 were primarily related to a pool of consumer loans charged-off in the third quarter of 2024. The net charge-offs recorded during the first quarter of 2024 were substantially related to a partial charge-off of the aforementioned pool of consumer loans.

The Company’s allowance for credit losses was 1.28% of total loans and 402.45% of nonperforming loans at March 31, 2025, compared with 1.27% of total loans and 433.77% of nonperforming loans at December 31, 2024. Allowance for credit losses on unfunded commitments was $1.4 million at March 31, 2025.

Deposits

	Three Months Ended												% Change  March 31, 2025  vs.
	March 31, 2025				December 31, 2024				March 31, 2024				December 31, 2024			March 31, 2024
	(Dollars in thousands)
Noninterest-bearing deposits	$	533,220			$	575,357			$	416,704			(7.3) %			28.0	%
Interest-bearing deposits		1,892,411				1,835,940				1,693,094			3.1	%		11.8	%
Total deposits	$	2,425,631			$	2,411,297			$	2,109,798			0.6	%		15.0	%
Uninsured deposits	$	760,379			$	760,141			$	610,122			—	%		24.6	%
Uninsured deposits to total deposits and accrued interest on deposits		31.33	%			31.50	%			28.92	%
Noninterest deposits to total deposits		21.98	%			23.86	%			19.75	%

Total deposits were $2.4 billion at March 31, 2025, $2.4 billion at December 31, 2024 and $2.1 billion at March 31, 2024. The $14.3 million increase in total deposits in the first quarter was primarily due to an increase of $56.5 million in interest-bearing deposits, which includes a $12.5 million increase in brokered deposits, partially offset by a $42.1 million decrease in noninterest-bearing deposits. Total brokered deposits were $162.5 million at March 31, 2025, compared to $150.0 million at December 31, 2024.

Capital

	March 31, 2025						December 31, 2024						March 31, 2024
	Company			Bank			Company			Bank			Company			Bank
Tier 1 capital ratio to average assets	9.14	%		11.99	%		8.67	%		11.45	%		8.79	%		11.67	%
Risk-based capital ratios:
Common equity tier 1 (“CET1”) capital ratio	10.18	%		13.35	%		9.84	%		12.99	%		9.39	%		12.47	%
Tier 1 capital ratio	10.18	%		13.35	%		9.84	%		12.99	%		9.39	%		12.47	%
Total capital ratio	15.06	%		14.55	%		14.73	%		14.18	%		14.42	%		13.63	%

As of March 31, 2025, total stockholders’ equity was $290.2 million, up from $279.9 million at December 31, 2024. The increase of $10.3 million was substantially due to earnings growth.

About Southern States Bancshares, Inc.

Headquartered in Anniston, Alabama, Southern States Bancshares, Inc. is a bank holding company that operates primarily through its wholly-owned subsidiary, Southern States Bank. The Bank is a full service community banking institution, which offers an array of deposit, loan and other banking-related products and services to businesses and individuals in its communities. The Bank operates 15 branches in Alabama and Georgia and two loan production offices in Atlanta.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which reflect our current expectations and beliefs with respect to, among other things, future events and our financial performance. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. This may be especially true given recent events and trends in the banking industry and the pending Merger. Although we believe that the expectations reflected in such forward-looking statements are reasonable as of the dates made, we cannot give any assurance that such expectations will prove correct and actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 under the section entitled “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors”. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict.

These statements are often, but not always, made through the use of words or phrases such as “may,” “can,” “should,” “could,” “to be,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “continue,” “will,” “likely,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “target,” “project,” “would” and “outlook,” or the negative version of those words or other similar words or phrases of a future or forward-looking nature. Forward-looking statements appear in a number of places in this press release and may include statements about our acquisition of Century Bank of Georgia, business strategy and prospects for growth, operations, ability to pay dividends, competition, regulation and general economic conditions.

Contact Information
Lynn Joyce				Margaret Boyce
(205) 820-8065				(310) 622-8247
[email protected]				[email protected]

SELECT FINANCIAL DATA
(Dollars in thousands, except share and per share amounts)
	Three Months Ended
	March 31, 2025				December 31, 2024				March 31, 2024
Results of Operations
Interest income	$	43,164			$	44,977			$	38,736
Interest expense		18,285				19,927				17,897
Net interest income		24,879				25,050				20,839
Provision for credit losses		775				72				1,236
Net interest income after provision		24,104				24,978				19,603
Noninterest income		1,653				2,990				1,268
Noninterest expense		12,306				13,074				10,375
Income tax expense		3,100				3,696				2,377
Net income	$	10,351			$	11,198			$	8,119
Core net income(1)	$	10,334			$	10,484			$	8,128
Share and Per Share Data
Shares issued and outstanding		9,922,180				9,889,260				8,894,794
Weighted average shares outstanding:
Basic		9,979,120				9,940,221				8,913,477
Diluted		10,072,329				10,061,735				9,043,122
Earnings per share:
Basic	$	1.04			$	1.13			$	0.91
Diluted		1.03				1.11				0.90
Core – diluted(1)		1.03				1.04				0.90
Book value per share		29.25				28.30				25.06
Tangible book value per share(1)		25.04				24.04				23.07
Cash dividends per common share		0.09				0.09				0.09
Performance and Financial Ratios
ROAA		1.48	%			1.55	%			1.33	%
ROAE		14.67	%			16.13	%			14.87	%
Core ROAA(1)		1.47	%			1.45	%			1.34	%
ROATCE(1)		17.19	%			18.87	%			16.17	%
Core ROATCE(1)		17.16	%			17.67	%			16.19	%
NIM		3.75	%			3.66	%			3.59	%
NIM – FTE(1)		3.76	%			3.67	%			3.60	%
Net interest spread		2.76	%			2.64	%			2.63	%
Yield on loans		6.93	%			7.03	%			7.06	%
Yield on interest-earning assets		6.51	%			6.57	%			6.67	%
Cost of interest-bearing liabilities		3.75	%			3.93	%			4.04	%
Cost of funds(2)		2.93	%			3.09	%			3.27	%
Cost of interest-bearing deposits		3.64	%			3.83	%			3.92	%
Cost of total deposits		2.80	%			2.96	%			3.12	%
Noninterest deposits to total deposits		21.98	%			23.86	%			19.75	%
Core deposits to total deposits		87.75	%			87.90	%			81.45	%
Uninsured deposits to total deposits and accrued interest on deposits		31.33	%			31.50	%			28.92	%
Total loans to total deposits		93.17	%			92.34	%			93.14	%
Efficiency ratio		46.42	%			46.67	%			46.90	%
Core efficiency ratio(1)		46.42	%			47.78	%			46.90	%

<sup>(1) See “Reconciliation of Non-GAAP Financial Measures” below for reconciliation of non-GAAP financial measures to their most closely comparable GAAP financial measures.

(2) Includes total interest-bearing liabilities and noninterest deposits.</sup>

SELECT FINANCIAL DATA
(Dollars in thousands)
	Three Months Ended
	March 31, 2025				December 31, 2024				March 31, 2024
Financial Condition (ending)
Total loans	$	2,260,036			$	2,226,569			$	1,965,149
Total securities		218,544				216,481				197,006
Total assets		2,851,145				2,848,254				2,510,975
Total noninterest bearing deposits		533,220				575,357				416,704
Total core deposits(1)		2,128,422				2,119,491				1,718,333
Total deposits		2,425,631				2,411,297				2,109,798
Total borrowings		111,382				131,224				146,773
Total liabilities		2,560,961				2,568,365				2,288,094
Total shareholders’ equity		290,184				279,889				222,881
Financial Condition (average)
Total loans	$	2,235,194			$	2,205,892			$	1,916,288
Total securities		228,396				228,213				208,954
Total other interest-earning assets		227,124				288,802				211,127
Total interest-bearing assets		2,690,714				2,722,907				2,336,369
Total assets		2,841,513				2,875,981				2,447,278
Total noninterest-bearing deposits		552,746				552,898				416,141
Total interest-bearing deposits		1,861,387				1,893,906				1,633,307
Total deposits		2,414,133				2,446,804				2,049,448
Total borrowings		113,728				121,356				148,771
Total interest-bearing liabilities		1,975,115				2,015,262				1,782,078
Total shareholders’ equity		286,126				276,250				219,622
Asset Quality
Nonperforming loans	$	7,175			$	6,533			$	3,446
Other real estate owned (“OREO”)	$	—			$	—			$	33
Nonperforming assets (“NPA”)	$	7,175			$	6,533			$	3,479
Net charge-offs (recoveries) to average loans(2)		0.04	%		(0.04)%					0.10	%
Provision for credit losses to average loans(2)		0.14	%			0.01	%			0.26	%
ACL to loans		1.28	%			1.27	%			1.28	%
ACL to gross loans		1.27	%			1.27	%			1.28	%
ACL to NPL		402.45	%			433.77	%			729.66	%
NPL to loans		0.32	%			0.29	%			0.18	%
NPL to gross loans		0.32	%			0.29	%			0.17	%
NPA to gross loans and OREO		0.32	%			0.29	%			0.18	%
NPA to total assets		0.25	%			0.23	%			0.14	%
Regulatory and Other Capital Ratios
Total shareholders’ equity to total assets		10.18	%			9.83	%			8.88	%
Tangible common equity to tangible assets(3)		8.84	%			8.47	%			8.23	%
Tier 1 capital ratio to average assets		9.14	%			8.67	%			8.79	%
Risk-based capital ratios:
CET1 capital ratio		10.18	%			9.84	%			9.39	%
Tier 1 capital ratio		10.18	%			9.84	%			9.39	%
Total capital ratio		15.06	%			14.73	%			14.42	%

<sup>(1) We define core deposits as total deposits excluding brokered deposits and time deposits greater than $250,000.

(2) Ratio is annualized.

(3) See “Reconciliation of Non-GAAP Financial Measures” below for reconciliation of non-GAAP financial measures to their most closely comparable GAAP financial measures.</sup>

CONSOLIDATED STATEMENTS OF FINANCIAL CONDITION
(Dollars in thousands)
	March 31, 2025				December 31, 2024				March 31, 2024
	(Unaudited)				(Audited)				(Unaudited)
Assets
Cash and due from banks	$	25,555			$	27,321			$	20,470
Interest-bearing deposits in banks		127,430				153,833				129,917
Federal funds sold		76,390				79,080				86,736
Total cash and cash equivalents		229,375				260,234				237,123
Securities available for sale, at fair value		198,938				196,870				177,379
Securities held to maturity, at amortized cost		19,606				19,611				19,627
Other equity securities, at fair value		2,754				3,697				3,638
Restricted equity securities, at cost		4,408				4,441				5,108
Loans held for sale		1,236				404				425
Loans, net of unearned income		2,260,036				2,226,569				1,965,149
Less allowance for credit losses		28,876				28,338				25,144
Loans, net		2,231,160				2,198,231				1,940,005
Premises and equipment, net		31,728				32,048				26,262
Accrued interest receivable		10,432				10,111				9,561
Bank owned life insurance		39,698				39,431				30,075
Annuities		16,794				16,772				15,939
Foreclosed assets		—				—				33
Goodwill		33,176				33,176				16,862
Core deposit intangible		8,539				8,939				817
Other assets		23,301				24,289				28,121
Total assets	$	2,851,145			$	2,848,254			$	2,510,975
Liabilities and Stockholders’ Equity
Liabilities:
Deposits:
Noninterest-bearing	$	533,220			$	575,357			$	416,704
Interest-bearing		1,892,411				1,835,940				1,693,094
Total deposits		2,425,631				2,411,297				2,109,798
Other borrowings		—				17,979				7,997
FHLB advances		20,000				22,000				52,000
Subordinated notes		91,382				91,245				86,776
Accrued interest payable		1,585				2,172				1,805
Other liabilities		22,363				23,672				29,718
Total liabilities		2,560,961				2,568,365				2,288,094
Stockholders’ equity:
Common stock		49,986				49,821				44,746
Capital surplus		107,480				106,637				79,282
Retained earnings		143,530				134,075				109,838
Accumulated other comprehensive loss		(7,503	)			(7,936	)			(8,401	)
Unvested restricted stock		(1,168	)			(567	)			(1,030	)
Vested restricted stock units		(2,141	)			(2,141	)			(1,554	)
Total stockholders’ equity		290,184				279,889				222,881
Total liabilities and stockholders’ equity	$	2,851,145			$	2,848,254			$	2,510,975

CONSOLIDATED STATEMENTS OF INCOME
(Dollars in thousands, except per share amounts)
	Three Months Ended
	March 31, 2025				December 31, 2024			March 31, 2024
	(Unaudited)				(Unaudited)			(Unaudited)
Interest income:
Loans, including fees	$	38,202			$	38,972		$	33,628
Taxable securities		2,239				2,237			1,981
Nontaxable securities		247				248			229
Other interest and dividends		2,476				3,520			2,898
Total interest income		43,164				44,977			38,736
Interest expense:
Deposits		16,689				18,223			15,906
Other borrowings		1,596				1,704			1,991
Total interest expense		18,285				19,927			17,897
Net interest income		24,879				25,050			20,839
Provision for credit losses		775				72			1,236
Net interest income after provision for credit losses		24,104				24,978			19,603
Noninterest income:
Service charges on deposit accounts		564				565			463
Swap (expenses) fees		(3	)			17			15
SBA/USDA fees		40				89			64
Mortgage origination fees		80				55			96
Net gain (loss) on securities		23				25			(12	)
Employee retention credit		—				1,154			—
Other operating income		949				1,085			642
Total noninterest income		1,653				2,990			1,268
Noninterest expenses:
Salaries and employee benefits		6,924				7,002			6,231
Equipment and occupancy expenses		828				851			689
Data processing fees		909				960			643
Regulatory assessments		429				441			360
Professional fees related to ERC		—				236			—
Other operating expenses		3,216				3,584			2,452
Total noninterest expenses		12,306				13,074			10,375
Income before income taxes		13,451				14,894			10,496
Income tax expense		3,100				3,696			2,377
Net income	$	10,351			$	11,198		$	8,119
Basic earnings per share	$	1.04			$	1.13		$	0.91
Diluted earnings per share	$	1.03			$	1.11		$	0.90

AVERAGE BALANCE SHEET AND NET INTEREST MARGIN
(Dollars in thousands)
	Three Months Ended
	March 31, 2025										December 31, 2024										March 31, 2024
	Average Balance				Interest			Yield/Rate			Average Balance				Interest			Yield/Rate			Average Balance				Interest			Yield/Rate
Assets:
Interest-earning assets:
Loans, net of unearned income(1)	$	2,235,194			$	38,202		6.93	%		$	2,205,892			$	38,972		7.03	%		$	1,916,288			$	33,628		7.06	%
Taxable securities		181,788				2,239		4.99	%			181,456				2,237		4.90	%			163,586				1,981		4.87	%
Nontaxable securities		46,608				247		2.15	%			46,757				248		2.11	%			45,368				229		2.03	%
Other interest-earnings assets		227,124				2,476		4.42	%			288,802				3,520		4.85	%			211,127				2,898		5.52	%
Total interest-earning assets	$	2,690,714			$	43,164		6.51	%		$	2,722,907			$	44,977		6.57	%		$	2,336,369			$	38,736		6.67	%
Allowance for credit losses		(28,430	)									(28,280	)									(24,313	)
Noninterest-earning assets		179,229										181,354										135,222
Total Assets	$	2,841,513									$	2,875,981									$	2,447,278
Liabilities and Stockholders’ Equity:
Interest-bearing liabilities:
Interest-bearing transaction accounts		95,573				20		0.09	%			94,039				27		0.12	%			85,858				26		0.12	%
Savings and money market accounts		1,120,998				9,765		3.53	%			1,112,679				10,279		3.68	%			902,361				8,804		3.92	%
Time deposits		644,816				6,904		4.34	%			687,188				7,917		4.58	%			645,088				7,076		4.41	%
FHLB advances		20,644				275		5.40	%			22,000				300		5.42	%			53,121				655		4.96	%
Other borrowings		93,084				1,321		5.76	%			99,356				1,404		5.63	%			95,650				1,336		5.62	%
Total interest-bearing liabilities	$	1,975,115			$	18,285		3.75	%		$	2,015,262			$	19,927		3.93	%		$	1,782,078			$	17,897		4.04	%
Noninterest-bearing liabilities:
Noninterest-bearing deposits	$	552,746									$	552,898									$	416,141
Other liabilities		27,526										31,571										29,437
Total noninterest-bearing liabilities	$	580,272									$	584,469									$	445,578
Stockholders’ Equity		286,126										276,250										219,622
Total Liabilities and Stockholders’ Equity	$	2,841,513									$	2,875,981									$	2,447,278
Net interest income					$	24,879									$	25,050									$	20,839
Net interest spread(2)								2.76	%									2.64	%									2.63	%
Net interest margin(3)								3.75	%									3.66	%									3.59	%
Net interest margin – FTE(4)(5)								3.76	%									3.67	%									3.60	%
Cost of funds(6)								2.93	%									3.09	%									3.27	%
Cost of interest-bearing deposits								3.64	%									3.83	%									3.92	%
Cost of total deposits								2.80	%									2.96	%									3.12	%

<sup>(1)   Includes nonaccrual loans.

(2)   Net interest spread is the difference between interest rates earned on interest earning assets and interest rates paid on interest-bearing liabilities.

(3)   Net interest margin is a ratio of net interest income to average interest earning assets for the same period.

(4)   Net interest margin – FTE is a ratio of fully-taxable equivalent net interest income to average interest earning assets for the same period. It assumes a 24.0% tax rate.

(5)   Refer to “Reconciliation of Non-GAAP Financial Measures”.

(6)   Includes total interest-bearing liabilities and noninterest deposits.</sup>

LOAN COMPOSITION
(Dollars in thousands)
	March 31, 2025							December 31, 2024							March 31, 2024
	Amount				% of gross			Amount				% of gross			Amount				% of gross
Real estate mortgages:
Construction and development	$	247,264			10.9	%		$	238,603			10.7	%		$	252,934			12.8	%
Residential		317,994			14.0	%			315,083			14.1	%			238,702			12.1	%
Commercial		1,356,064			59.8	%			1,350,091			60.4	%			1,182,634			60.0	%
Commercial and industrial		333,831			14.8	%			317,887			14.3	%			288,701			14.7	%
Consumer and other		11,587			0.5	%			11,580			0.5	%			8,425			0.4	%
Gross loans		2,266,740			100.0	%			2,233,244			100.0	%			1,971,396			100.0	%
Unearned income		(6,704	)						(6,675	)						(6,247	)
Loans, net of unearned income		2,260,036							2,226,569							1,965,149
Allowance for credit losses		(28,876	)						(28,338	)						(25,144	)
Loans, net	$	2,231,160						$	2,198,231						$	1,940,005

DEPOSIT COMPOSITION
(Dollars in thousands)
	March 31, 2025						December 31, 2024						March 31, 2024
	Amount			% of total			Amount			% of total			Amount			% of total
Noninterest-bearing transaction	$	533,220		22.0	%		$	575,357		23.8	%		$	416,704		19.7	%
Interest-bearing transaction		1,183,984		48.8	%			1,128,959		46.8	%			974,079		46.2	%
Savings		54,795		2.3	%			52,472		2.2	%			33,909		1.6	%
Time deposits, $250,000 and under		518,958		21.4	%			512,717		21.3	%			584,658		27.7	%
Time deposits, over $250,000		134,674		5.5	%			141,792		5.9	%			100,448		4.8	%
Total deposits	$	2,425,631		100.0	%		$	2,411,297		100.0	%		$	2,109,798		100.0	%

Nonperfoming Assets
(Dollars in thousands)
	March 31, 2025				December 31, 2024				March 31, 2024
Nonaccrual loans	$	7,175			$	6,434			$	3,446
Past due loans 90 days or more and still accruing interest		—				99				—
Total nonperforming loans		7,175				6,533				3,446
OREO		—				—				33
Total nonperforming assets	$	7,175			$	6,533			$	3,479
Financial difficulty modification loans– nonaccrual(1)		543				600				675
Financial difficulty modification loans – accruing		1,029				1,055				1,283
Financial difficulty modification loans	$	1,572			$	1,655			$	1,958
Allowance for credit losses	$	28,876			$	28,338			$	25,144
Loans, net of unearned income at the end of the period	$	2,260,036			$	2,226,569			$	1,965,149
Gross loans outstanding at the end of period	$	2,266,740			$	2,233,244			$	1,971,396
Total assets	$	2,851,145			$	2,848,254			$	2,510,975
Allowance for credit losses to nonperforming loans		402.45	%			433.77	%			729.66	%
Nonperforming loans to loans, net of unearned income		0.32	%			0.29	%			0.18	%
Nonperforming loans to gross loans		0.32	%			0.29	%			0.17	%
Nonperforming assets to gross loans and OREO		0.32	%			0.29	%			0.18	%
Nonperforming assets to total assets		0.25	%			0.23	%			0.14	%
Nonaccrual loans by category:
Real estate mortgages:
Construction & Development	$	403			$	415			$	—
Residential Mortgages		758				559				246
Commercial Real Estate Mortgages		2,694				2,097				2,422
Commercial & Industrial		3,320				3,363				778
Consumer and other		—				—				—
Total	$	7,175			$	6,434			$	3,446

^{(1) Financial difficulty modification loans are excluded from nonperforming loans unless they otherwise meet the definition of nonaccrual loans or are more than 90 days past due.}

Allowance for Credit Losses
(Dollars in thousands)
	Three Months Ended
	March 31, 2025				December 31, 2024				March 31, 2024
Average loans, net of unearned income	$	2,235,194			$	2,205,892			$	1,916,288
Loans, net of unearned income		2,260,036				2,226,569				1,965,149
Gross loans		2,266,740				2,233,244				1,971,396
Allowance for credit losses at beginning of the period		28,338				28,061				24,378
Charge-offs:
Construction and development		—				—				—
Residential		—				—				11
Commercial		—				—				27
Commercial and industrial		331				—				442
Consumer and other		2				—				15
Total charge-offs		333				—				495
Recoveries:
Construction and development		—				—				—
Residential		6				7				8
Commercial		—				—				—
Commercial and industrial		89				196				16
Consumer and other		1				2				1
Total recoveries		96				205				25
Net charge-offs (recoveries)	$	237			$	(205	)		$	470
Provision for credit losses	$	775			$	72			$	1,236
Balance at end of the period	$	28,876			$	28,338			$	25,144
Allowance for credit losses on unfunded commitments at beginning of the period	$	1,405			$	1,405			$	1,239
Provision for credit losses on unfunded commitments		—				—				49
Balance at the end of the period	$	1,405			$	1,405			$	1,288
Allowance to loans, net of unearned income		1.28	%			1.27	%			1.28	%
Allowance to gross loans		1.27	%			1.27	%			1.28	%
Net charge-offs (recoveries) to average loans, net of unearned income(1)		0.04	%		(0.04) %					0.10	%
Provision for credit losses to average loans, net of unearned income(1)		0.14	%			0.01	%			0.26	%

(1) Ratio is annualized.

Reconciliation of Non-GAAP Financial Measures

In addition to reporting GAAP results, the Company reports non-GAAP financial measures in this earnings release and other disclosures. Our management believes that these non-GAAP financial measures and the information they provide are useful to investors since these measures permit investors to view our performance using the same tools that our management uses to evaluate our performance. While we believe that these non-GAAP financial measures are useful in evaluating our performance, this information should be considered as supplemental in nature and not as a substitute for or superior to the related financial information prepared in accordance with GAAP. Additionally, these non-GAAP financial measures may differ from similar measures presented by other companies.

The following table provides a reconciliation of the non-GAAP financial measures to their most directly comparable financial measure presented in accordance with GAAP.

Reconciliation of Non-GAAP Financial Measures
(Dollars in thousands, except share and per share amounts
	Three Months Ended
	March 31, 2025				December 31, 2024				March 31, 2024
Net income	$	10,351			$	11,198			$	8,119
Add: Professional fees related to ERC		—				236				—
Add: Net OREO gains		—				3				—
Less: Employee retention related revenue		—				1,154				—
Less: Net gain (loss) on securities		23				25				(12	)
Less: Tax effect		(6	)			(226	)			3
Core net income	$	10,334			$	10,484			$	8,128
Average assets	$	2,841,513			$	2,875,981			$	2,447,278
Core return on average assets		1.47	%			1.45	%			1.34	%
Net income	$	10,351			$	11,198			$	8,119
Add: Professional fees related to ERC		—				236				—
Add: Net OREO gains		—				3				—
Add: Provision for credit losses		775				72				1,236
Less: Employee retention related revenue		—				1,154				—
Less: Net gain (loss) on securities		23				25				(12	)
Add: Income taxes		3,100				3,696				2,377
Pretax pre-provision core net income	$	14,203			$	14,026			$	11,744
Average assets	$	2,841,513			$	2,875,981			$	2,447,278
Pretax pre-provision core return on average assets		2.03	%			1.94	%			1.93	%
Net interest income	$	24,879			$	25,050			$	20,839
Add: Fully-taxable equivalent adjustments(1)		62				66				73
Net interest income – FTE	$	24,941			$	25,116			$	20,912
Net interest margin		3.75	%			3.66	%			3.59	%
Effect of fully-taxable equivalent adjustments(1)		0.01	%			0.01	%			0.01	%
Net interest margin – FTE		3.76	%			3.67	%			3.60	%
Total stockholders’ equity	$	290,184			$	279,889			$	222,881
Less: Intangible assets		41,715				42,115				17,679
Tangible common equity	$	248,469			$	237,774			$	205,202
(1) Assumes a 24.0% tax rate.
Reconciliation of Non-GAAP Financial Measures
(Dollars in thousands, except share and per share amounts
	Three Months Ended
	March 31, 2025				December 31, 2024				March 31, 2024
Core net income	$	10,334			$	10,484			$	8,128
Diluted weighted average shares outstanding		10,072,329				10,061,735				9,043,122
Diluted core earnings per share	$	1.03			$	1.04			$	0.90
Common shares outstanding at year or period end		9,922,180				9,889,260				8,894,794
Tangible book value per share	$	25.04			$	24.04			$	23.07
Total assets at end of period	$	2,851,145			$	2,848,254			$	2,510,975
Less: Intangible assets		41,715				42,115				17,679
Adjusted assets at end of period	$	2,809,430			$	2,806,139			$	2,493,296
Tangible common equity to tangible assets		8.84	%			8.47	%			8.23	%
Total average shareholders equity	$	286,126			$	276,250			$	219,622
Less: Average intangible assets		41,957				40,177				17,730
Average tangible common equity	$	244,169			$	236,073			$	201,892
Net income to common shareholders	$	10,351			$	11,198			$	8,119
Return on average tangible common equity		17.19	%			18.87	%			16.17	%
Average tangible common equity	$	244,169			$	236,073			$	201,892
Core net income	$	10,334			$	10,484			$	8,128
Core return on average tangible common equity		17.16	%			17.67	%			16.19	%
Net interest income	$	24,879			$	25,050			$	20,839
Add: Noninterest income		1,653				2,990				1,268
Less: Employee retention related revenue		—				1,154				—
Less: Net gain (loss) on securities		23				25				(12	)
Operating revenue	$	26,509			$	26,861			$	22,119
Expenses:
Total noninterest expense	$	12,306			$	13,074			$	10,375
Less: Professional fees related to ERC		—				236				—
Less: Net OREO gains		—				3				—
Adjusted noninterest expenses	$	12,306			$	12,835			$	10,375
Core efficiency ratio		46.42	%			47.78	%			46.90	%

ACHESON, Alberta, April 21, 2025 (GLOBE NEWSWIRE) — North American Construction Group Ltd. (“NACG” or “the Company”) (TSX:NOA.TO/NYSE:NOA) announced today that it will release its financial results for the first quarter ended March 31, 2025 on Wednesday, May 14, 2025 after markets close. Following the release of its financial results, NACG will hold a conference call and webcast on Thursday, May 15, 2025, at 7:00 a.m. Mountain Time (9:00 a.m. Eastern Time).

The call can be accessed by dialing:
Toll free: 1-800-717-1738
Conference ID: 42703

A replay will be available through June 12, 2025, by dialing:
Toll Free: 1-888-660-6264
Conference ID: 42703
Playback Passcode: 42703

A slide deck for the webcast will be available for download the evening prior to the call and will be found on the company’s website at www.nacg.ca/presentations/

The live presentation and webcast can be accessed at: North American Construction Group Ltd. First Quarter Results Conference Call and Webcast Registration

A replay will be available until June 12, 2025, using the link provided.

About the Company

North American Construction Group Ltd. is a premier provider of heavy civil construction and mining services in Australia, Canada, and the U.S. For over 70 years, NACG has provided services to the mining, resource and infrastructure construction markets.

For further information, please contact:        

Jason Veenstra, CPA, CA
Chief Financial Officer
North American Construction Group Ltd.
Phone: (780) 960-7171
Email: [email protected]

CUPERTINO, Calif., April 21, 2025 (GLOBE NEWSWIRE) — Aemetis, Inc. (NASDAQ: AMTX), a diversified global renewable natural gas and biofuels company, announced the Company’s subsidiary in India, Universal Biofuels, received multiple orders for an aggregate of $31 million for the delivery during May, June and July of more than 33,000 kiloliters of biodiesel to the three government-owned Oil Marketing Companies (OMCs).  

Additional OMC orders are expected throughout the year in order to continue shipments to fuel blending terminals on an ongoing basis to support the India government goal of increasing from a 1% to 5% biodiesel blend.

”Universal Biofuels and other biodiesel producers look forward to continuous support from the government of India to ensure that climate issues are addressed, while ensuring a healthy biodiesel industry,” stated Sanjeev Duggal, CEO of Universal Biofuels.

“We are pleased with the progress being made in India in support of the 5% biodiesel blending target of more than 1.2 billion gallons per year,” stated Eric McAfee, Chairman and CEO of Aemetis.  “The OMCs did not take deliveries during this past winter and instead decided to issue new orders for biodiesel with deliveries from May to July. Our Universal Biofuels subsidiary has successfully completed deliveries under contracts with the OMCs for the past several years, highlighting our track record for producing and timely delivering high quality renewable fuels at our India plant.”

Recently, India achieved a 20% ethanol blend into gasoline and the government stated a new 30% blend target for ethanol, enabling further growth in ethanol production and expanding revenues for farmers while reducing the importation of petroleum gasoline into India.

Universal Biofuels significantly expanded the production capacity of the Kakinada biodiesel plant to 80 million gallons per year during a recent plant upgrade and maintenance cycle, including expansion of its proprietary process that produces biodiesel from waste and byproducts that Universal utilizes to produce biofuels that are lower carbon intensity at a significantly reduced cost. 

Aemetis’ Universal Biofuels subsidiary is one of the largest biodiesel producers in India, having been in operation for more than 17 years. Universal Biofuels increased annual biodiesel capacity from 50 million gallons to 80 million gallons last year, with further biodiesel expansion to other locations and diversification into biogas production planned for 2025. To support further growth, Universal Biofuels is preparing for an IPO in India which is expected to be completed in late 2025, subject to continued favorable stock market conditions.

Universal Biofuels completed $112 million of biodiesel and glycerine shipments in the twelve months ended September 2024, including deliveries to the three government-owned oil marketing companies under a cost-plus contract. Shipments of biodiesel to OMC’s are expected to begin in early May under the next round of biodiesel contracts. 

About Aemetis

Headquartered in Cupertino, California, Aemetis is a renewable natural gas and renewable fuel company focused on the operation, acquisition, development, and commercialization of innovative technologies that replace petroleum products and reduce greenhouse gas emissions. Founded in 2006, Aemetis is operating and actively expanding a California biogas digester network and pipeline system to convert dairy waste gas into Renewable Natural Gas. Aemetis owns and operates a 65 million gallon per year ethanol production facility in California’s Central Valley near Modesto that supplies about 80 dairies with animal feed. Aemetis owns and operates an 80 million gallon per year production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin. Aemetis is developing a sustainable aviation fuel plant and a CO2 sequestration project in California. For additional information about Aemetis, please visit www.aemetis.com. 

Safe Harbor Statement

This news release contains forward-looking statements, including statements regarding assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements include, without limitation, projections of financial results; statements related to the development, engineering, financing, construction and operation of the Aemetis biodiesel and other biofuel facilities; our ability to promote, develop, finance, and construct facilities to produce biodiesel, renewable fuels, and biochemicals; and statements about future market prices and results of government actions. Words or phrases such as “anticipates,” “may,” “will,” “should,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “showing signs,” “targets,” “view,” “will likely result,” “will continue” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol, biodiesel and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, customer adoption, counter-party risks, risks associated with changes to federal policy or regulation, and other risks detailed in our reports filed with the Securities and Exchange Commission, including our Annual Reports on Form 10-K, and in our other filings with the SEC. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.

Company Investor Relations

Media Contact:

Todd Waltz
(408) 213-0940
[email protected]

External Investor Relations

Contact:

Kirin Smith
PCG Advisory Group
(646) 863-6519
[email protected]

— Integration of clinical and patient-reported outcomes expected to further differentiate EluPro’s utility in cardiac implantable electronic device (CIED) procedures —

SILVER SPRING, Md., April 21, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the initiation of an EluPro™ clinical study designed to collect patient outcome data in real-world clinical practice. EluPro, the first and only FDA-cleared antibiotic-eluting bioenvelope designed for use with cardiac implantable electronic devices (CIEDs) and neurostimulators, was commercially launched earlier this year. The first patient was enrolled at UC San Diego Health.

“Every innovation we pursue is driven by a commitment to improving patient care,” said Kimberly Mulligan, PhD, Vice President and General Manager of Cardiovascular at Elutia. “With EluPro, we combined trusted antibiotics with a soft, regenerative biomatrix to protect the implant, facilitate implantation, and support healing. This study will allow us to collect data on these differentiating characteristics in real-world practice.”

The multi-center clinical study is a prospective, post-market study designed to evaluate the use of EluPro in standard clinical practice and its performance across a diverse population of patients undergoing CIED implantation. Data on clinical and patient-reported outcomes will be collected, which will include assessments of key complications of interest following CIED implantation – such as infection, hematoma, lead dislodgement, device migration or erosion, and implant site complications. The study plans to enroll 100 patients, who will be followed for 12 months after device implantation.

Each year, more than 600,000 CIEDs are implanted in the U.S., with overall complication rates up to 5-7%, including infections linked to higher morbidity and mortality. EluPro is cleared for use across all major CIED brands including pacemakers and implantable defibrillators, as well as for a wide range of neurostimulation devices. Unlike synthetic alternatives, EluPro addresses this critical need by combining the antibiotics rifampin and minocycline with a soft, regenerative biomatrix that promotes healing and helps reduce other complications, such as migration and erosion. The CIED protection market is valued at $600 million in the U.S.

To learn more, visit www.elutia.com/products/elupro/.

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including any statements and information concerning the EluPro Registry Study, including the timing and anticipated data, and the value of the CIED protection market. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to the following: our ability to successfully commercialize, market and sell our newly approved EluPro product; our ability to continue as a going concern; our ability to achieve or sustain profitability; the risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; our ability to defend against the various lawsuits and claims related to our recalled FiberCel and other viable bone matrix products and avoid a material adverse financial consequence from those lawsuits and claims; the continued and future acceptance of our products by the medical community; our ability to enhance our products, expand our product indications and develop, acquire and commercialize additional product offerings; our dependence on our commercial partners and independent sales agents to generate a substantial portion of our net sales; our dependence on a limited number of third-party suppliers and manufacturers, which, in certain cases are exclusive suppliers for products essential to our business; our ability to successfully realize the anticipated benefits of the November 2023 sale of our Orthobiologics business; physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products; our ability to compete against other companies, most of which have longer operating histories, more established products and/or greater resources than we do; pricing pressure as a result of cost-containment efforts of our customers, purchasing groups, third-party payors and governmental organizations could adversely affect our sales and profitability; our ability to obtain regulatory approval or other marketing authorizations by the FDA and comparable foreign authorities for our products and product candidates; and our ability to obtain, maintain and adequately protect our intellectual property rights; and other important factors which can be found in the “Risk Factors” section of Elutia’s public filings with the Securities and Exchange Commission (“SEC”), including Elutia’s Annual Report on Form 10-K for the year ended December 31, 2024, as such factors may be updated from time to time in Elutia’s other filings with the SEC, accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Elutia’s website at https://investors.elutia.com. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement made by Elutia in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investors:

Matt Steinberg
FINN Partners
[email protected]

This press release was published by a CLEAR® Verified individual.

AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) — BigCommerce (Nasdaq: BIGC), a leading provider of open, composable commerce solutions for B2C and B2B brands and retailers, today announced the winners of the 2025 BigCommerce and Feedonomics Customer and Partner Awards in the Americas region. The awards programs recognize the most innovative and inspiring customers and partners doing big things on the BigCommerce and Feedonomics platforms.

“These awards recognize the outstanding achievements of BigCommerce customers and partners across the Americas,” said John Huntington, senior vice president of global partnerships at BigCommerce. “Our partners continue to prioritize innovation and customer success, playing a vital role in helping brands, retailers, manufacturers, and distributors thrive. We are equally proud of our customers, whose innovation and success on our platform inspire us every day.”

“It’s incredibly rewarding to celebrate the achievements of our customers and partners,” said Sharon Gee, senior vice president and general manager of Feedonomics. “These award recipients are true innovators and industry leaders, and we’re proud to recognize their forward-thinking strategies. Our partners continue to drive meaningful digital growth by embracing cutting-edge approaches, from leveraging predictive signals in product feeds to launching local inventory ad programs and replacing outdated systems to maximize results.”

This year’s AMER awards featured 24 categories across BigCommerce and Feedonomics customers and partners with applicants evaluated by a panel of BigCommerce and Feedonomics employees and executives. The awards recognized one winner for each category based on their accomplishments.

2025 BigCommerce Customer Award Winners

Achievement in Growth: Highlighting exceptional growth and success achieved with BigCommerce.

• Winner:
  
  Sleep Country Canada
  
  

B2B Excellence Award: Recognizing leadership in B2B ecommerce that redefines what’s possible

• Winner:
  
  Movora
  
  

Design Award: Celebrating captivating storefront designs that inspire and engage customers.

• Winner:
  
  Walden Local Meat
  
  

Shopper Experience Award: Acknowledging exceptional customer and user experiences that set new standards.

• Winner:
  
  Moore & Giles
  
  

Innovation Award: Honoring cutting-edge solutions that push the boundaries of ecommerce.

• Winner:
  
  King Arthur Baking
  
  

2025 Feedonomics Customer Award Winners

Feedonomics Innovative Integration Award:
Recognizing
the customer who has demonstrated exceptional creativity and innovation in integrating Feedonomics into their business operations.

• Winner: 1-800-FLOWERS

Feedonomics Exemplary Efficiency Award: Honoring the customer who has achieved outstanding operational efficiency by leveraging Feedonomics.

• Winner: Lowe’s Companies

Feedonomics Global Expansion Award:
Acknowledging the customer who has successfully utilized Feedonomics to expand their business into new international markets.

• Winner: Fox Racing/Revelyst

Feedonomics Achievement in Growth: Presented to the customer who has shown exceptional growth and success with Feedonomics.

• Winner: DoorDash

2025 BigCommerce Agency Partner Winners

Agency Partner of the Year: Awarded to the partner with the best overall performance across metrics and collaboration efforts in EMEA as a whole between January 1, 2024 – December 31, 2024.

• Winner:
  
  Mojo Active
  
  

Agency B2B Excellence Award: Awarded to agency partners that have a background in B2B problem solving, efficiencies and utilize B2B-centric product features and who consistently demonstrate superiority at meeting the complex needs of BigCommerce’s B2B customers.

• Winner: Silk Commerce

Catalyst Delivery Award: Awarded to an agency partner that leveraged Catalyst to deliver custom development work blending content and experience-driven functionality, unlocking BigCommerce’s full potential.

• Winner:
  
  Mira Commerce
  
  

User Experience & Design Award: Awarded to agency partners who create world-class, visually appealing designs that enhance user experience, drive interactivity, and increase conversions.

• Winner: Brilliance Business Solutions

Creative Problem Solving Award: Awardedto agency partners who have created a world class, visually appealing design that enhances the user experience and leads to higher interactivity and conversion.

• Winner: CQL

Excellence in Delivery Award: Awarded to agency partners that consistently demonstrate the ability to successfully launch their clients’ BigCommerce storefronts on time and on budget, with high levels of customer satisfaction.

• Winner: EPAM

2025 BigCommerce Technology Partner Winners

Tech Partner of the Year Award: Awarded to technology partners whose integration features a superior user experience demonstrated by a high volume of installation and positive user reviews plus successful co-marketing activity over the last year.

• Winner: Klaviyo

Innovative Integration Award: Awarded to technology partners that have built a new integration or feature that solves a critical need for BigCommerce customers.

• Winner: ResolvePay

Customer Growth Award: Awarded to technology partners whose outstanding solution has generated the most revenue growth for BigCommerce customers, while aligning with BigCommerce initiatives.

• Winner: TradeCentric

Technology B2B Excellence Award: Awarded to tech partners that have a background in B2B problem solving, efficiencies and utilize B2B-centric product features and who consistently demonstrate superiority at meeting the complex needs of BigCommerce’s B2B customers.

• Winner: BlueSnap

Emerging Partner: Celebrates a rising tech partner with superior user experience, growing installs and excellent reviews.

• Winner: Wayflyer

2025 Feedonomics Partner Winners

Feedonomics Partner of the Year: Awarded to the Omnichannel Certified Agency that sourced the highest revenue for Feedonomics.

• Winner: Power Digital

Innovation A
ward: Recognizing an innovative partnership with a leading global consultative, creative, and marketing agency to disrupt and replace legacy technology with Feedonomics’ industry leading data and feed management platform.

• Winner: Walmart

Emerging Partner: Celebrates a rising agency partner that has shown exceptional promise and leadership.

• Winner: MediaScale Partners

To join the BigCommerce and Feedonomics ecosystem of agency and technology partners, click here.

About BigCommerce

BigCommerce (Nasdaq: BIGC) is a leading open SaaS and composable ecommerce platform that empowers brands, retailers, manufacturers and distributors of all sizes to build, innovate and grow their businesses online. BigCommerce provides its customers sophisticated professional-grade functionality, customization and performance with simplicity and ease-of-use. Tens of thousands of B2C and B2B companies across 150 countries and numerous industries rely on BigCommerce, including Coldwater Creek, Harvey Nichols, King Arthur Baking Co., MKM Building Supplies, United Aqua Group and Uplift Desk. For more information, please visit www.bigcommerce.com or follow us on X and LinkedIn.

About Feedonomics

Feedonomics is the leading data management platform powering omnichannel growth for the world’s top brands and retailers. With its flexible technology and full-service support team, Feedonomics facilitates a variety of data and order management use cases across industries such as ecommerce, automotive, employment, travel, real estate, and more. Feedonomics has thousands of active customers, integrations with hundreds of ecommerce platforms and channels, and strategic partnerships with industry leaders like Amazon, Meta, Google, Microsoft and TikTok. For more information, please visit www.feedonomics.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

BigCommerce® is a registered trademark of BigCommerce Pty. Ltd. Third-party trademarks and service marks are the property of their respective owners.

Media Contact:

Brad Hem
[email protected]

BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class¹ targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin (PGE2) signaling, for the treatment of patients with Familial Adenomatous Polyposis (FAP).

“Receiving orphan drug designation for TPST-1495, our second clinical program, is a significant milestone in our mission to bring innovative therapies to patients with unmet medical need,” said Stephen Brady, President and CEO of Tempest. “This designation for the treatment of FAP underscores Tempest’s mission to make a meaningful difference in the lives of patients and builds on the momentum from prior designations received for amezalpat in hepatocellular carcinoma.”

A Phase 2 study evaluating TPST-1495 in patients with FAP is set to begin this year, conducted by the Cancer Prevention Clinical Trials Network and funded by the National Cancer Institute (NCI) Division of Cancer Prevention. Data from this study are expected in 2026.

About Familial Adenomatous Polyposis

FAP is a high-risk inherited syndrome associated with the development of cancer in affected patients and has no approved medical therapies. In the US, the disease affects approximately one in 5,000 to 10,000 individuals². FAP is caused by autosomal dominant inactivating mutations in the tumor suppressor gene APC. Patients with FAP develop large numbers of adenomatous polyps throughout the gastrointestinal tract, often starting in their teenage years. These growths have a high risk of malignant transformation and can give rise to invasive cancers of the colon, stomach, duodenum, rectum, and other tissues. Standard of care treatment for patients with FAP is surgical removal of the colon (colectomy) early in life to reduce the likelihood of cancer development. Even after colectomy, patients must receive careful surveillance for development of cancer elsewhere in the GI tract throughout their lifetime. While surgical management and surveillance have improved the prognosis for patients with FAP, cancer remains a major cause of death for patients with FAP.  

1	If approved by the FDA
2	Rarediseases.org/rare-diseases/familial-adenomatous-polyposis/

About Orphan Drug Designation

The FDA’s Orphan Drug Designation program provides orphan status to therapies intended for the treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 people in the United States. This designation provides certain benefits, including tax credits for qualified clinical testing, waiver or partial payment of FDA application fees and seven years of market exclusivity, if approved.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined under the federal securities laws, that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. Forward-looking statements contained in this press release include but are not limited to statements relating to: the initiation, timing and results of the Phase 2 study for TPST-1495; and the ability of TPST-1495 to benefit from the ODD designation, including potential tax credits and market exclusivity. Any forward-looking statements in this press release are based on Tempest Therapeutics’ current expectations, estimates and projections about its industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks relating to: changes in the regulatory environment resulting in potentials delays in the clinical development and regulatory approval of our product candidates, including TPST-1495; the volatility and uncertainty in the capital markets for biotechnology companies; and our ability to raise additional capital or other pursue our plan to identify and complete a strategic transaction on attractive terms or at all. These and other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the “Risk Factors” section of the company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on March 27, 2025, as well as in other filings the company may make with the SEC in the future. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest Therapeutics’ views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics.

Investor & Media Contacts:

Sylvia Wheeler
Wheelhouse Life Science Advisors
[email protected]

Aljanae Reynolds
Wheelhouse Life Science Advisors
[email protected]

i

If approved by the FDA

ST. LOUIS, April 21, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced today it will host a live demonstration of the GenesisX Robotic System at this year’s Heart Rhythm Symposium (HRS), taking place April 24 – 27 in San Diego, CA. This marks the first live, public demonstration of GenesisX, offering a glimpse to HRS attendees into the robot’s revolutionary clinical capabilities and “weekend” installation.

GenesisX represents the latest advance in endovascular surgical robotics, building upon the proven benefits of Robotic Magnetic Navigation while significantly enhancing accessibility for healthcare providers. The system features a compact and efficient design, incorporating magnetic shielding into its structure to eliminate the need for room-based shielding, reducing infrastructure requirements. GenesisX operates on standard 120/230V power, requires no structural anchoring, and features an 80% smaller system cabinet that conveniently fits under an operating room table. The system’s smaller and lighter design enhances workflow efficiency while maintaining the highest standards in speed and responsiveness.

Stereotaxis will be located at Booth 1034 and will be featured during several events throughout the congress, including:

• Stereotaxis Investor Technology Demonstration: Friday April 25^th at 12:00 PM PDT
• Joint Session with Africa Heart Rhythm Association on leveraging telerobotics to advance care in underserved communities: Saturday April 26^th at 2:45 PM PDT
• Joint Session of HRS & Society for Cardiac Robotic Navigation (SCRN): April 27^th at 12:45 PM PDT

“We are thrilled to bring GenesisX to HRS and allow the electrophysiology community to experience firsthand this cutting-edge innovation along with our expanding portfolio of proprietary catheters and digital technologies,” said David Fischel, Stereotaxis Chairman and CEO. “We look forward to engaging with the electrophysiology community at HRS, who, together with us, are pioneering the frontiers of medicine.”

GenesisX obtained CE Mark approval in Europe in 2024 and is currently under review for FDA 510(k) clearance in the United States. In addition to GenesisX, Stereotaxis will showcase its portfolio of compatible EP and vascular catheters, including the Map-iT™, MAGiC™, and EMAGIN™ product lines, as well as its advanced Synchrony™ and SynX™ digital lab technologies.

If you are interested in a meeting to learn more about GenesisX or other Stereotaxis technology, please contact [email protected].

About Stereotaxis


Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control and may be revised, modified, delayed, or canceled.

Stereotaxis Contacts:

David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
[email protected]

TEL AVIV, Israel, April 21, 2025 (GLOBE NEWSWIRE) — Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that clinical data on nebokitug (CM-101) for the treatment of patients with primary sclerosing cholangitis (PSC) will be presented at major upcoming scientific conferences including DDW25, Digestive Disease Week 2025^®; EASL 2025, the Annual Congress of the European Association for the Study of the Liver; and BSG LIVE’25, the British Society of Gastroenterology’s annual meeting. Chemomab will report information on the content of the presentations after the meeting embargoes lift.

DDW25, May 3-6, 2025, San Diego, USA
Date:	May 4, 2025
Time:	4:00 – 5:30pm PDT
Format:	Oral presentation: CM-101, a novel monoclonal antibody targeting CCL24, was safe, well-tolerated and showed improvements of biomarkers associated with inflammation, fibrosis and cholestasis in patients with primary sclerosing cholangitis (PSC): The Spring Study
Presenter:	Paul Pockros, MD, Director, Liver Disease Scripps Clinic and SC Liver Disease Consortium
Session:	Liver & Biliary Section Distinguished Abstract Plenary
Information:	https://ddw.org/
EASL 2025, May 7-10, 2025, Amsterdam, Netherlands
Date:	May 8, 2025
Time:	8:30-17:30 CEDT
Format:	Poster presentation: CM-101 impacts disease biomarkers in primary sclerosing cholangitis: assessment of the SPRING study pharmacokinetics and pharmacodynamics
Presenter:	Adi Mor, PhD, co-founder and CEO, Chemomab
Session:	Immune-mediated and cholestatic disease: Clinical aspects; Abstract #1255
Information:	https://www.easlcongress.eu
EASL 2025, May 7-10, 2025, Amsterdam, Netherlands
Date:	May 9, 2025
Time:	8:30-17:30 CEDT
Format:	Poster presentation: CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes
Presenter:	Adi Mor, PhD, co-founder and CEO, Chemomab
Session:	Immune-mediated and cholestatic: Experimental and pathophysiology; Abstract #1243
Information:	https://www.easlcongress.eu
BSG Live’25, June 23-26, 2025, Glasgow, UK
Date:	June 23-26, 2025
Time:	TBD
Format:	Oral presentation: CM-101, a novel monoclonal antibody targeting CCL24, in patients with primary sclerosing cholangitis: results from SPRING Study
Presenter:	Douglas Thorburn, MD, Divisional Clinical Director for Liver and Digestive Health at the Royal Free London NHS Trust and Professor of Hepatology in the Institute for Liver and Digestive Health at UCL
Session:	Liver
Information:	https://live.bsg.org.uk/

     

About Chemomab Therapeutics Ltd.

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of nebokitug in patients. Based on positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company is preparing for potential initiation of a nebokitug PSC Phase 3 trial. The design of Phase 3 calls for a single pivotal trial based on a clinical event primary endpoint that provides a clear and streamlined pathway to potential full regulatory approval. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab’s nebokitug program for the treatment of systemic sclerosis has an open U.S. IND. For more information, visit: chemomab.com.
  
Contacts:

Media and Investors:

Barbara Lindheim
Consulting Vice President, Investor & Public Relations, Strategic Communications
Phone: +1 917-355-9234
[email protected]
[email protected]